January 31, 2017 2:54pm

Financial results/ earnings is a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.

 

The current LPS (loss per share) standings reflect the universes’ investing status; then add in their cash position for a better snapshot!

By analyzing these comparisons, investors can begin to gauge the financial health versus the scientific opportunity and whether or not it deserves their investment.


COMPANY SYMBOL NET INCOME Q4/16 LOSS Q4/16 LPS Q4/16 CASH 
Aduro Biotech, Inc. ADRO        
Applied Genetic Technologies AGTC        
Asterias Biotherapeutics AST        
Athersys, Inc. ATHX        
Adverum Biotechnologies, Inc. ADVM        
AxoGen, Inc. AXGN        
Bellicum Pharmaceuticals, Inc. BLCM        
BioLife Solutions, Inc. BLFS        
Biostage, Inc. BSTG        
BioTime, Inc. BTX        
bluebird bio BLUE        
Brainstorm Cell Therapeutics Inc. BCLI        
Caladrius Biosciences. CLBS        
Capricor CAPR        
Cellectis CLLS        
Cesca Therapeutics, Inc KOOL        
Cytori Therapeutics, Inc. CYTX        
Fate Therapeutics, Inc. FATE        
Fibrocell Science, Inc. FCSC        
Histogenics Corporation HSGX        
ImmunoCellular Therapeutics, Ltd. IMUC        
International Stem Cell ISCO        
Intrexon Corporation XON        
Juno Therapeutics, Inc. JUNO        
Kite Pharma, Inc. KITE        
Mesoblast Limited MBLTY        
MiMedx Group, Inc MDXG        
Neuralstem, Inc.  CUR        
Northwest Biotherapeutics, Inc. NWBO        
Opexa Therapeutic, Inc. OPXA        
Organovo Holdings, Inc. ONVO        
Osiris Therapeutics, Inc. OSIR        
Pluristem Therapeutics, Inc. PSTI        
ReNeuron Group PLC RENE.L        
Regenxbio RGNX        
Sangamo Biosciences, Inc. SGMO        
Spark Therapeutics, Inc. ONCE        
StemCells, Inc. STEM        
Stemline Therapeutics, Inc. STML        
uniQure N.V. QURE    
Verastem, Inc. VSTM        
Vericel Corporation VCEL        
VistaGen Therapeutics, Inc. VTGN